Integrated Diagnostics Holdings PLC

Director's Dealing • Oct 8, 2024

National Storage Mechanism | Additional information

RNS Number : 4282H

Integrated Diagnostics Holdings PLC

08 October 2024

Integrated Diagnostics Holdings plc

(the "Company")

Cancellation of Treasury Shares

08 October 2024

The Company today announces the cancellation of 18,673,728 treasury shares initially transferred to treasury on the Completion of Treasury Shares Removal Process referred to in the Company's announcement on 18 September 2024.

In accordance with Listing Rule 9.8.2 the Company discloses the following information:

Date of cancellation	08 October 2024
Number of ordinary shares held in treasury cancelled	18,673,728
Total number of ordinary shares held in treasury following the cancellation	0
Total number of ordinary shares in issue following the cancellation (excluding shares held in treasury)	581,326,272

For further information please contact:

Integrated Diagnostics Holdings plc

Tarek Yehia

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 |        [email protected]

Company Secretary

Company Matters

[email protected]

-Ends-

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of   clinical   pathology and radiology tests to patients in Egypt, Jordan,   Nigeria,   Sudan and   Saudi Arabia. The   Group's   core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan),   Echo-Lab (Nigeria),   Ultralab and Al Mokhtabar Sudan (both in Sudan ),   and   Biolab KSA (Saudi Arabia).  With over 40 years of experience, a   long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over   3   ,000 diagnostics tests. From its base of   601   branches as of 31 December   2023 , IDH served over 8.   5   million patients and   performed   more than   36.1   million tests in   2023.    IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion.  Beyond organic growth, the   Group targets   expansion   in appealing markets, including   acquisitions in   the   Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets.  IDH is a Jersey-registered entity whose Shares are admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange since May 2015 (ticker: IDHC).

Learn more at   idhcorp.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSUWANRSWURRAA